ClinicalTrials.gg
TerminatedNCT05999799AtDventureUpdated Jun 3, 2026Results posted

A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of GSK1070806 and Placebo in Dermatitis, Atopic, sponsored by GlaxoSmithKline. Terminated at 89 sites in 17 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision to early terminate the study based on the pre-defined futility criterion for efficacy. No safety concerns were identified.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Dermatitis, Atopic by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Dermatitis, Atopic · GlaxoSmithKline.

Enrollment
5th of 18
161 · median 42
Started
2023
the only one that year
Phase 2
8 of 19
none open now
Registered
18th of 19
by date

Among the 19 studies in Dermatitis, Atopic by GlaxoSmithKline, this one is the 5th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2023, is one of 8 in phase 2, and was the 18th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 19 studies in Dermatitis, Atopic by GlaxoSmithKline is open now. The open studies under Dermatitis, Atopic, anywhere →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Dermatitis, Atopic by GlaxoSmithKline as a file.
02

Study summary

This study is parallel group, placebo-controlled dose-ranging study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of GSK1070806 in adult participants with moderate to severe Atopic Dermatitis (AtD), who have previously been treated with medicated topical treatments or a biologic therapy.

03

Conditions studied

  • Dermatitis, Atopic

Keywords

  • Dermatitis
  • Atopic
  • GSK1070806
  • 219538
  • Eczema
  • Skin Diseases
  • Safety
  • Efficacy
  • Immune System Diseases
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants 18 years to 75 years of age
  • Participants with:

    • AtD defined by the AAD Consensus Criteria.
    • Diagnosis of AtD ≥1 year.
    • An IGA score ≥3.
    • AtD involvement of ≥10% body surface area (BSA).
    • EASI score ≥16
    • Baseline pruritus numerical rating scale average score for maximum intensity of at least 3.
  • Participants may have had exposure to 1 biologic therapy meeting at least 1 of the following conditions:

    • Participants who stopped treatment due to non-response, partial response, loss of efficacy.
    • Participants who stopped treatment due to intolerance or AEs.
  • Participant with a recent history less than or equal to (≤6) months prior to the Screening visit) of inadequate response to a stable regimen of prescription topical medication.
  • Participants for whom prescription topical medications are not tolerated.
  • use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical study

Exclusion criteria

Exclusion Criteria:

  • Chronic or acute infection requiring treatment with oral or IV antibiotics, antivirals, anti-protozoal, or antifungals within 4 weeks before the Screening visit or anytime between the Screening and Baseline visits.
  • Superficial skin infections within 1 week before the Screening visit or active infections (including localized infections), or history of recurrent infections (excluding recurrent fungal infections of the nail bed)
  • Known, pre-existing or suspected parasitic infection within 6 months before the Screening visit.
  • Symptomatic herpes zoster within 3 months prior to screening
  • Uncontrolled hypertension.
  • Current or chronic history of liver disease or known hepatic or biliary abnormalities.
  • Known or suspected history of , including history of invasive opportunistic infections despite infection resolution or unusually frequent, recurrent, or prolonged infections, per the Investigator's judgment.
  • Lymphoma, leukemia, or any within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of disease for 3 years
  • Breast cancer within the past 10 years.
  • History or presence of significant medical illness including but not limited to cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, neurological, or psychiatric disorders which in the opinion of the investigator would interfere with the study procedures and/or assessments.
  • Previously treated with any oral Janus Kinase inhibitor (JAKi) or other kinase inhibitors, experimental or approved.
  • Uncontrolled chronic disease that might require bursts of oral , e.g., co-morbid severe uncontrolled asthma.
  • Presence of surface antibody (HBsAg) or Hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention.
  • Positive antibody test result at screening or within 3 months prior to starting study intervention.
  • Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.
  • Positive antibody test.
  • Evidence of active or latent TB as documented by medical history, examination, and TB testing with a positive QuantiFERON test at initial Screening visit.
  • Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
161 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received placebo subcutaneous (SC) injections for 16 weeks.

    Drug: Placebo

  • Experimental
    GSK1070806 Dose Level 1

    Participants received GSK1070806 dose level 1 SC injection for 16 weeks. Dose level 1 is the lowest dose level.

    Drug: GSK1070806

  • Experimental
    GSK1070806 Dose Level 2

    Participants received GSK1070806 dose level 2 SC injection for 16 weeks. Dose level 2 is greater than dose level 1.

    Drug: GSK1070806

  • Experimental
    GSK1070806 Dose Level 3

    Participants received GSK1070806 dose level 3 SC injection for 16 weeks. Dose level 3 is greater than dose level 2.

    Drug: GSK1070806

  • Experimental
    GSK1070806 Dose Level 4

    Participants received GSK1070806 dose level 4 SC injection for 16 weeks. Dose level 4 is greater than dose level 3.

    Drug: GSK1070806

Interventions

  • GSK1070806 will be administered.

  • DrugPlacebo

    Placebo will be administered.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline (CFB) in Eczema Area and Severity Index (EASI) Score at Week 16

    EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline=last value/assessment before first dose of study treatment (ST) (Day1) based on date \& time of assessment (ToA) \& treatment. CFB =post-dose visit (Week 16) value minus Baseline value. Percent CFB was calculated by dividing CFB value by Baseline value and multiplying it by 100.

    Time frame: Baseline (Day 1) and Week 16

Secondary outcomes

  1. Percent Change From Baseline (CFB) in EASI Score at Each Time Point

    EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline=last value/assessment before first dose of ST (Day1) based on date \& ToA \& treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Percent CFB was calculated by dividing CFB value by Baseline value and multiplying it by 100.

    Time frame: Baseline (Day 1), Weeks 1, 2, 4, 6, 8, 10, 12, 14, and 16

  2. Number of Participants Who Achieved Reduction of Greater Than or Equal to (>=) 75 Percent (%) in EASI Score From Baseline at Week 16

    EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline was the last value/assessment before first dose of study treatment (Day1) based on date \& time of assessment \& treatment.

    Time frame: Baseline (Day 1) and Week 16

  3. Number of Participants Who Achieved Investigator's Global Assessment (IGA) Score of 0 or 1 and Had a Reduction of >=2 Points From Baseline at Week 16

    The Investigator Global Assessment (IGA) is a clinical tool for assessing the current state/severity of a participant's atopic dermatitis. It is a static 5-point morphological assessment of overall disease severity determined by the investigator, sub-investigator, or trained healthcare professional with required qualifications on a scale of 0 to 4 where, 0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe. Higher score indicates high severity of disease. IGA 0/1 responders are participants whose IGA score is 'Clear' (0) or 'Almost Clear' (1) and had a reduction of \>=2 points from Baseline at Week 16. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment.

    Time frame: Baseline (Day 1) and Week 16

  4. Change From Baseline in Peak Pruritus Numerical Rating Scale (PP-NRS) Score at Week 16

    PP-NRS is a patient reported measure of pruritus (itch) intensity assessing worst itch (in the past 24 hours). The values were evaluated using an 11-point scale (from 0 to 10), with 0 being no itch and 10 being the worst imaginable itch. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113). Change from Baseline (CFB) was calculated by subtracting Baseline value from the post-dose (PD) visit (Week 16) value.

    Time frame: Baseline (Day -7 to Day -1) and Week 16

  5. Number of Participants Who Achieved Reduction of >=4 Points in PP-NRS Score From Baseline at Week 16

    PP-NRS is a patient reported measure of pruritus (itch) intensity assessing worst itch (in the past 24 hours). The values were evaluated using an 11-point scale (from 0 to 10), with 0 being no itch and 10 being the worst imaginable itch. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113).

    Time frame: Baseline (Day -7 to Day -1) and Week 16

  6. Number of Participants Who Achieved Reduction of >=50%, >=90% or 100% in EASI Score From Baseline at Week 16

    EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline was the last value/assessment before first dose of study treatment (Day 1) based on date \& time of assessment \& treatment.

    Time frame: Baseline (Day 1) and Week 16

  7. Number of Participants Who Achieved Reduction of >=50% or >=75% in Scoring Atopic Dermatitis (SCORAD) Score From Baseline at Week 16

    SCORAD was used to standardize the extent and severity of AtD. It consisted of 3 components i.e., A=extent or affected BSA assessed as a % of each defined body area and reported as sum of all areas, with a maximum score of 100%.B=severity of 6 specific symptoms of AtD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none=0,mild=1,moderate=2, or severe=3 (for a maximum of 18 total points) \& C=pruritus (itch) \& sleep loss scored by participants on VAS, where "0"=no itch(or no sleeplessness) \& "10"=worst imaginable itch(or sleeplessness) with a maximum score of 20. SCORAD total score was calculated using these 3 aspects: extent (A: 0-100), severity (B: 0-18), \& subjective symptoms (C: 0-20) using the formula: A/5 + 7\*B/2+ C. SCORAD total score ranged from 0 to 103, where 0=no disease to 103=severe disease. Higher values of SCORAD=worse outcome.

    Time frame: Baseline (Day 1) and Week 16

  8. Change From Baseline in the Body Surface Area (BSA) at Week 16

    The BSA assessment estimates the extent of disease or skin involvement with respect to AtD and is expressed as a percentage of total body surface area. BSA were determined by the Investigator or designee using the participant's palm = 1% rule i.e. the surface area of the participant's palm (including fingers) is approximately 1% of the total BSA. Investigators applied this rule to quickly estimate the percentage of skin affected by AtD without complex calculations (for example- if the affected area equals 10 palms, this corresponded to approximately 10% BSA involvement). Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  9. Change From Baseline in the SCORAD Score at Week 16

    SCORAD was used to standardize the extent and severity of AtD. It consisted of 3 components i.e., A=extent or affected BSA assessed as a % of each defined body area and reported as sum of all areas, with a maximum score of 100%.B=severity of 6 specific symptoms of AtD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none=0,mild=1,moderate=2, or severe=3 (for a maximum of 18 total points) \& C=pruritus (itch) \& sleep loss scored by participants on VAS, where "0"=no itch(or no sleeplessness) \& "10"=worst imaginable itch(or sleeplessness) with a maximum score of 20. SCORAD total score was calculated using these 3 aspects: extent (A: 0-100), severity (B: 0-18), \& subjective symptoms (C: 0-20) using the formula: A/5 + 7\*B/2+ C. SCORAD total score ranged from 0 to 103, where 0=no disease to 103=severe disease. Higher values of SCORAD=worse outcome.

    Time frame: Baseline (Day 1) and Week 16

  10. Change From Baseline in Patient Reported Outcomes (PRO) Measure of Skin Pain Numerical Rating Scale (SP-NRS) Score at Week 16

    SP-NRS is a patient reported measure assessing worst level of skin pain (in the past 24 hours). The values were evaluated using an 11-point scale from 0 to 10, with 0 being no pain and 10 being the worst pain imaginable. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day -7 to Day -1) and Week 16

  11. Change From Baseline in PRO Measure of Patient Reported Outcomes Measurement Information System (PROMIS) -Sleep Disturbance 8b at Week 16

    The PROMIS sleep disturbance 8b is a PRO instrument designed to assess participant's self-reported sleep disturbance for which the recall period is the past 7 days. It measures perceptions of sleep quality, depth, and restoration associated with sleep. It contains 8 questions (hence "8b"), these questions are rated using 5-point verbal rating scale (i.e., 1 = very much to 5 = not at all). These are summed to get a total score which ranges from 8 to 40, with higher scores indicating greater severity of sleep disturbance. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  12. Change From Baseline in PRO Measure of Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score at Week 16

    The FACIT-Fatigue scale is a short, 13-item measure that assesses participant's self-reported fatigue and its associated impact for daily activities over the past week. The items are rated on a 5-point Likert-type scale: (i.e., 0 = very much to 4 = not at all), where a higher score indicates a better outcome (no fatigue). The total score was derived by summing rating of all 13 items, which ranges from 0 to 52, with 0 being the worst possible score and 52 indicating no fatigue. Higher score indicates an improvement in the participant's health status and decrease in the score indicates worse fatigue/quality of life (QoL). Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  13. Change From Baseline in PRO Measure of Brief Fatigue Inventory (BFI) - Item 3 at Week 16

    The BFI is a self-administered questionnaire developed to assess fatigue severity. The BFI has 9 items. BFI- Item 3 assesses the worst level of fatigue during the past 24 hours. Participants report their worst level of fatigue daily, for the previous 24 hours, using a numerical rating scale ranging from 0 (no fatigue) to 10 (as bad as you can imagine). The BFI item 3 score ranges from 0 to 10, higher score indicates worst outcome. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day -7 to Day -1) and Week 16

  14. Change From Baseline in PRO Measure of Patient Oriented Eczema Measure (POEM) at Week 16

    POEM is a 7-item questionnaire that assesses symptoms of dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping over the last week. Each item is scored from 0 to 4, where 0 = 'no days', 1 = '1 to 2 days', 2 = '3 to 4 days', 3 = '5 to 6' days, and 4 = 'every day'). The total score was derived by summing scores of all 7-items. Total score ranges from 0 (absent disease) to 28 (severe disease). Higher score indicates poor QoL. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose (Week 16) visit value.

    Time frame: Baseline (Day 1) and Week 16

  15. Change From Baseline in PRO Measure of Dermatology Life Quality Index (DLQI) Score at Week 16

    The DLQI is a 10-item questionnaire that asks participants to evaluate the degree that their skin disease has affected their QoL. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score. The total DLQI score ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impaired quality of life. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  16. Change From Baseline in PRO Measure of Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale Score at Week 16

    HADS was a validated 14-item self-reported questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale. HADS-A assessed state of generalized anxiety. It comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 (no, not at all) to 3 (yes, definitely), where higher scores indicated more anxiety/depression symptoms. HADS-A total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicated greater severity of anxiety. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value. Data of HADS-anxiety subscale score has been presented.

    Time frame: Baseline (Day 1) and Week 16

  17. Change From Baseline in PRO Measure of HADS-Depression Subscale Score at Week 16

    HADS was a validated 14-item self-reported questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale. HADS-D assessed state of depression. It comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 (no, not at all) to 3 (yes, definitely), where higher scores indicated more anxiety/depression symptoms. HADS-D total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicated greater severity of depression. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value. Data of HADS-depression subscale score has been presented.

    Time frame: Baseline (Day 1) and Week 16

  18. Change From Baseline in PRO Measure of Work Productivity and Activity Impairment Questionnaire-Atopic Dermatitis (WPAI- AD) at Week 16

    The WPAI-AD is a concise,6-item questionnaire that evaluates the impact of atopic dermatitis on both work and daily activities, yielding 4 percentage-based impairment scores, each range from 0 to 100%. Higher values=greater impairment. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism) (%)=hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) \*100. 2. Impairment while working due to health (Presenteeism) (%)=Question (Q)5 score (from 0 to 10) divided by 10\*100. 3. Overall work impairment due to health (%)=Absenteeism+(1-Absenteeism fraction)\*Presenteeism. 4. Activity impairment due to health (%)=Q6 score (from 0 to 10) divided by 10\*100.Baseline was the last value/assessment before the first dose of study treatment (Day1) based on date and time of the assessment and treatment. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  19. Number of Participants With Adverse Events (AEs), Serious AE (SAEs), and AEs of Special Interest (AESI)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with use of a study intervention, whether or not considered related to study intervention. Any untoward medical occurrence that, at any dose, results in death, Is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes, Is a suspected transmission of any infectious agent via an authorized medicinal product and medically important were categorized as SAE. AESIs of the study drug includes serious and opportunistic infections, serious hypersensitivity reactions and injection site reactions.

    Time frame: Up to Week 28

  20. Change From Baseline in Hematology Parameter: Hemoglobin (Hb)

    Blood samples were collected to analyze hematology parameter: hemoglobin. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  21. Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets

    Blood samples were collected to analyze Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  22. Change From Baseline in Hematology Parameter: Erythrocytes

    Blood samples were collected to analyze hematology parameter: erythrocytes. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  23. Change From Baseline in Hematology Parameter: Hematocrit

    Blood samples were collected to analyze hematology parameter: hematocrit. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  24. Change From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio

    Blood samples were collected to analyze hematology parameter: Prothrombin International Normalized Ratio. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  25. Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma-Glutamyl Transferase (GGT)

    Blood samples were collected to analyze clinical chemical parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma-Glutamyl Transferase (GGT). Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  26. Change From Baseline in Clinical Chemistry Parameter: Total Bilirubin, Direct Bilirubin, and Creatinine

    Blood samples were collected to analyze clinical chemical parameters: Total Bilirubin, Direct Bilirubin, and Creatinine. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  27. Change From Baseline in Chemistry Parameters: Glucose and Urea

    Blood samples were collected to analyze chemistry parameters: glucose and urea. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  28. Change From Baseline in Chemistry Parameter: Albumin

    Blood samples were collected to analyze chemistry parameter: albumin. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  29. Change From Baseline in Chemistry Parameter: Estimated Glomerular Filtration Rate

    Blood samples were collected to analyze chemistry parameter: Estimated Glomerular Filtration Rate. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

    Time frame: Baseline (Day 1) and Week 16

  30. Number of Participants With Greater Than or Equal to (>=) Grade 3 Hematological/Clinical Chemistry Abnormalities According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)

    The laboratory measurements included hematology and clinical chemistry. The parameters evaluated were albumin, glomerular filtration rate from creatinine adjusted for body surface area, glucose, potassium, sodium, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatinine, gamma glutamyl transferase, activated partial thromboplastin time, hemoglobin, leukocytes, lymphocytes, neutrophils, platelets, prothrombin international normalized ratio, eosinophils, and fibrinogen. Worst case grade increase from Baseline grade was evaluated for all the laboratory tests that were gradable by NCI CTCAE. Data is presented for only those parameters for which participants had worst case \>= Grade 3 abnormalities.

    Time frame: Up to Week 28

07

Results

Posted Jun 3, 2026

Participant flow

A total of 161 participants were enrolled and randomized, however only 159 participants were included in Full Analysis Set (FAS) as 2 participants were never dosed following randomization. FAS included all randomized participants who received at least 1 dose of study treatment. This population was based on the treatment the participant was randomized to. This study was terminated after meeting the pre-defined futility criteria for efficacy.

Participant flow — Overall Study
MilestonePlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Started4622252246
Full analysis set (fas)4621252146
Completed2616181430
Not completed2067816
Withdrew: Lost to follow-up11000
Withdrew: Physician decision00001
Withdrew: Withdrawal by subject90134
Withdrew: Study terminated by sponsor1046411
Withdrew: Randomized, but did not receive treatment01010

Outcome measures

PrimaryPercent Change From Baseline (CFB) in Eczema Area and Severity Index (EASI) Score at Week 16

EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline=last value/assessment before first dose of study treatment (ST) (Day1) based on date \& time of assessment (ToA) \& treatment. CFB =post-dose visit (Week 16) value minus Baseline value. Percent CFB was calculated by dividing CFB value by Baseline value and multiplying it by 100.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Percent Change
Percent Change From Baseline (CFB) in Eczema Area and Severity Index (EASI) Score at Week 16
Percent ChangePlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Percent Change From Baseline (CFB) in Eczema Area and Severity Index (EASI) Score at Week 16-44.53 ± 40.805-42.86 ± 36.186-69.95 ± 33.363-41.49 ± 43.341-58.08 ± 33.129
SecondaryPercent Change From Baseline (CFB) in EASI Score at Each Time Point

EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline=last value/assessment before first dose of ST (Day1) based on date \& ToA \& treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Percent CFB was calculated by dividing CFB value by Baseline value and multiplying it by 100.

Time frame:
Baseline (Day 1), Weeks 1, 2, 4, 6, 8, 10, 12, 14, and 16
Reported as:
Mean · Percent Change
Percent Change From Baseline (CFB) in EASI Score at Each Time Point
Percent ChangePlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Week 1-9.58 ± 27.102-26.85 ± 25.180-27.05 ± 27.533-27.44 ± 29.177-14.64 ± 31.257
Week 2-26.81 ± 32.253-22.63 ± 27.981-38.13 ± 25.719-21.03 ± 26.151-27.31 ± 30.798
Week 4-26.75 ± 32.894-26.10 ± 27.041-48.22 ± 26.242-21.80 ± 39.642-42.85 ± 33.409
Week 6-30.94 ± 40.673-26.32 ± 46.858-59.53 ± 26.937-24.34 ± 46.323-53.15 ± 26.140
Week 8-35.38 ± 37.223-21.48 ± 65.594-58.61 ± 29.369-29.42 ± 44.434-58.66 ± 26.807
Week 10-37.23 ± 34.334-39.35 ± 32.049-62.04 ± 29.196-30.54 ± 51.927-58.73 ± 31.518
Week 12-44.80 ± 32.803-40.72 ± 32.538-64.63 ± 33.270-38.07 ± 49.963-59.34 ± 30.652
Week 14-47.10 ± 34.574-44.43 ± 32.007-66.16 ± 31.768-40.57 ± 57.553-63.84 ± 27.548
Week 16-44.53 ± 40.805-42.86 ± 36.186-69.95 ± 33.363-41.49 ± 43.341-58.08 ± 33.129
SecondaryNumber of Participants Who Achieved Reduction of Greater Than or Equal to (>=) 75 Percent (%) in EASI Score From Baseline at Week 16

EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline was the last value/assessment before first dose of study treatment (Day1) based on date \& time of assessment \& treatment.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Reduction of Greater Than or Equal to (>=) 75 Percent (%) in EASI Score From Baseline at Week 16
ParticipantsPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Number of Participants Who Achieved Reduction of Greater Than or Equal to (>=) 75 Percent (%) in EASI Score From Baseline at Week 165410310
SecondaryNumber of Participants Who Achieved Investigator's Global Assessment (IGA) Score of 0 or 1 and Had a Reduction of >=2 Points From Baseline at Week 16

The Investigator Global Assessment (IGA) is a clinical tool for assessing the current state/severity of a participant's atopic dermatitis. It is a static 5-point morphological assessment of overall disease severity determined by the investigator, sub-investigator, or trained healthcare professional with required qualifications on a scale of 0 to 4 where, 0=clear, 1=almost clear, 2=mild, 3=moderate, and 4=severe. Higher score indicates high severity of disease. IGA 0/1 responders are participants whose IGA score is 'Clear' (0) or 'Almost Clear' (1) and had a reduction of \>=2 points from Baseline at Week 16. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Investigator's Global Assessment (IGA) Score of 0 or 1 and Had a Reduction of >=2 Points From Baseline at Week 16
ParticipantsPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Number of Participants Who Achieved Investigator's Global Assessment (IGA) Score of 0 or 1 and Had a Reduction of >=2 Points From Baseline at Week 1634506
SecondaryChange From Baseline in Peak Pruritus Numerical Rating Scale (PP-NRS) Score at Week 16

PP-NRS is a patient reported measure of pruritus (itch) intensity assessing worst itch (in the past 24 hours). The values were evaluated using an 11-point scale (from 0 to 10), with 0 being no itch and 10 being the worst imaginable itch. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113). Change from Baseline (CFB) was calculated by subtracting Baseline value from the post-dose (PD) visit (Week 16) value.

Time frame:
Baseline (Day -7 to Day -1) and Week 16
Reported as:
Mean · Scores on a Scale
Change From Baseline in Peak Pruritus Numerical Rating Scale (PP-NRS) Score at Week 16
Scores on a ScalePlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in Peak Pruritus Numerical Rating Scale (PP-NRS) Score at Week 16-2.15 ± 2.745-1.77 ± 2.240-3.09 ± 2.129-2.55 ± 2.586-2.09 ± 2.376
SecondaryNumber of Participants Who Achieved Reduction of >=4 Points in PP-NRS Score From Baseline at Week 16

PP-NRS is a patient reported measure of pruritus (itch) intensity assessing worst itch (in the past 24 hours). The values were evaluated using an 11-point scale (from 0 to 10), with 0 being no itch and 10 being the worst imaginable itch. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113).

Time frame:
Baseline (Day -7 to Day -1) and Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Reduction of >=4 Points in PP-NRS Score From Baseline at Week 16
ParticipantsPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Number of Participants Who Achieved Reduction of >=4 Points in PP-NRS Score From Baseline at Week 1654635
SecondaryNumber of Participants Who Achieved Reduction of >=50%, >=90% or 100% in EASI Score From Baseline at Week 16

EASI scoring system is standardized clinical tool for assessment of extent (area) \& severity of atopic dermatitis(AtD). Severity of clinical signs of AtD (erythema, induration/papulation, excoriation \& lichenification) scored separately for each of 4 body regions (head \& neck, upper limbs, trunk \& lower limbs) on 4-point scale: 0=absent;1=mild;2=moderate;3=severe. EASI area score was based upon % body surface area with AtD in body region:0=0%, 1=1-9%;2=10-29%;3=30-49%;4=50-69%;5=70-89%;6=90-100%. Final EASI score was obtained by multiplying EASI area scores (0-6) with severity scores (0-3) of all 4 body regions; it ranges from 0 to 72, with higher scores= more severe or extensive condition. Baseline was the last value/assessment before first dose of study treatment (Day 1) based on date \& time of assessment \& treatment.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Reduction of >=50%, >=90% or 100% in EASI Score From Baseline at Week 16
ParticipantsPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Reduction of >=50% in EASI11714819
Reduction of >=90% in EASI21806
Reduction of 100% in EASI01101
SecondaryNumber of Participants Who Achieved Reduction of >=50% or >=75% in Scoring Atopic Dermatitis (SCORAD) Score From Baseline at Week 16

SCORAD was used to standardize the extent and severity of AtD. It consisted of 3 components i.e., A=extent or affected BSA assessed as a % of each defined body area and reported as sum of all areas, with a maximum score of 100%.B=severity of 6 specific symptoms of AtD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none=0,mild=1,moderate=2, or severe=3 (for a maximum of 18 total points) \& C=pruritus (itch) \& sleep loss scored by participants on VAS, where "0"=no itch(or no sleeplessness) \& "10"=worst imaginable itch(or sleeplessness) with a maximum score of 20. SCORAD total score was calculated using these 3 aspects: extent (A: 0-100), severity (B: 0-18), \& subjective symptoms (C: 0-20) using the formula: A/5 + 7\*B/2+ C. SCORAD total score ranged from 0 to 103, where 0=no disease to 103=severe disease. Higher values of SCORAD=worse outcome.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Reduction of >=50% or >=75% in Scoring Atopic Dermatitis (SCORAD) Score From Baseline at Week 16
ParticipantsPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Reduction of >=50% in SCORAD41826
Reduction of >=75% in SCORAD01201
SecondaryChange From Baseline in the Body Surface Area (BSA) at Week 16

The BSA assessment estimates the extent of disease or skin involvement with respect to AtD and is expressed as a percentage of total body surface area. BSA were determined by the Investigator or designee using the participant's palm = 1% rule i.e. the surface area of the participant's palm (including fingers) is approximately 1% of the total BSA. Investigators applied this rule to quickly estimate the percentage of skin affected by AtD without complex calculations (for example- if the affected area equals 10 palms, this corresponded to approximately 10% BSA involvement). Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Percentage of Body Surface Area
Change From Baseline in the Body Surface Area (BSA) at Week 16
Percentage of Body Surface AreaPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in the Body Surface Area (BSA) at Week 16-15.26 ± 20.869-11.21 ± 13.244-23.57 ± 19.012-4.39 ± 24.591-16.16 ± 11.932
SecondaryChange From Baseline in the SCORAD Score at Week 16

SCORAD was used to standardize the extent and severity of AtD. It consisted of 3 components i.e., A=extent or affected BSA assessed as a % of each defined body area and reported as sum of all areas, with a maximum score of 100%.B=severity of 6 specific symptoms of AtD (redness, swelling, oozing/crusting, excoriation, skin thickening/lichenification, dryness) assessed using following scale: none=0,mild=1,moderate=2, or severe=3 (for a maximum of 18 total points) \& C=pruritus (itch) \& sleep loss scored by participants on VAS, where "0"=no itch(or no sleeplessness) \& "10"=worst imaginable itch(or sleeplessness) with a maximum score of 20. SCORAD total score was calculated using these 3 aspects: extent (A: 0-100), severity (B: 0-18), \& subjective symptoms (C: 0-20) using the formula: A/5 + 7\*B/2+ C. SCORAD total score ranged from 0 to 103, where 0=no disease to 103=severe disease. Higher values of SCORAD=worse outcome.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Scores on a Scale
Change From Baseline in the SCORAD Score at Week 16
Scores on a ScalePlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in the SCORAD Score at Week 16-19.73 ± 19.060-14.69 ± 17.500-39.04 ± 14.701-20.18 ± 10.072-22.09 ± 17.458
SecondaryChange From Baseline in Patient Reported Outcomes (PRO) Measure of Skin Pain Numerical Rating Scale (SP-NRS) Score at Week 16

SP-NRS is a patient reported measure assessing worst level of skin pain (in the past 24 hours). The values were evaluated using an 11-point scale from 0 to 10, with 0 being no pain and 10 being the worst pain imaginable. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day -7 to Day -1) and Week 16
Reported as:
Mean · Scores on a Scale
Change From Baseline in Patient Reported Outcomes (PRO) Measure of Skin Pain Numerical Rating Scale (SP-NRS) Score at Week 16
Scores on a ScalePlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in Patient Reported Outcomes (PRO) Measure of Skin Pain Numerical Rating Scale (SP-NRS) Score at Week 16-2.0 ± 3.03-1.6 ± 2.26-3.0 ± 2.08-2.5 ± 2.78-2.0 ± 2.43
SecondaryChange From Baseline in PRO Measure of Patient Reported Outcomes Measurement Information System (PROMIS) -Sleep Disturbance 8b at Week 16

The PROMIS sleep disturbance 8b is a PRO instrument designed to assess participant's self-reported sleep disturbance for which the recall period is the past 7 days. It measures perceptions of sleep quality, depth, and restoration associated with sleep. It contains 8 questions (hence "8b"), these questions are rated using 5-point verbal rating scale (i.e., 1 = very much to 5 = not at all). These are summed to get a total score which ranges from 8 to 40, with higher scores indicating greater severity of sleep disturbance. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Scores on a Scale
Change From Baseline in PRO Measure of Patient Reported Outcomes Measurement Information System (PROMIS) -Sleep Disturbance 8b at Week 16
Scores on a ScalePlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in PRO Measure of Patient Reported Outcomes Measurement Information System (PROMIS) -Sleep Disturbance 8b at Week 16-5.29 ± 9.281-4.83 ± 8.330-9.70 ± 7.864-5.89 ± 7.846-5.27 ± 7.402
SecondaryChange From Baseline in PRO Measure of Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score at Week 16

The FACIT-Fatigue scale is a short, 13-item measure that assesses participant's self-reported fatigue and its associated impact for daily activities over the past week. The items are rated on a 5-point Likert-type scale: (i.e., 0 = very much to 4 = not at all), where a higher score indicates a better outcome (no fatigue). The total score was derived by summing rating of all 13 items, which ranges from 0 to 52, with 0 being the worst possible score and 52 indicating no fatigue. Higher score indicates an improvement in the participant's health status and decrease in the score indicates worse fatigue/quality of life (QoL). Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Scores on a Scale
Change From Baseline in PRO Measure of Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score at Week 16
Scores on a ScalePlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in PRO Measure of Functional Assessment of Chronic Illness Therapy (FACIT) - Fatigue Scale Score at Week 165.30 ± 10.3636.26 ± 11.80810.57 ± 10.8652.33 ± 7.2197.14 ± 11.738
SecondaryChange From Baseline in PRO Measure of Brief Fatigue Inventory (BFI) - Item 3 at Week 16

The BFI is a self-administered questionnaire developed to assess fatigue severity. The BFI has 9 items. BFI- Item 3 assesses the worst level of fatigue during the past 24 hours. Participants report their worst level of fatigue daily, for the previous 24 hours, using a numerical rating scale ranging from 0 (no fatigue) to 10 (as bad as you can imagine). The BFI item 3 score ranges from 0 to 10, higher score indicates worst outcome. Baseline was averaged from daily values from Day -7 to Day -1 prior to first dose of study treatment (Day 1); post-dose visit i.e. Week 16 used average of 7 daily values from Days 106 to 112 prior to Week 16 (Day 113). Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day -7 to Day -1) and Week 16
Reported as:
Mean · Scores on a Scale
Change From Baseline in PRO Measure of Brief Fatigue Inventory (BFI) - Item 3 at Week 16
Scores on a ScalePlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in PRO Measure of Brief Fatigue Inventory (BFI) - Item 3 at Week 16-1.59 ± 2.999-1.20 ± 1.974-2.59 ± 2.441-2.12 ± 2.469-1.84 ± 2.241
SecondaryChange From Baseline in PRO Measure of Patient Oriented Eczema Measure (POEM) at Week 16

POEM is a 7-item questionnaire that assesses symptoms of dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping over the last week. Each item is scored from 0 to 4, where 0 = 'no days', 1 = '1 to 2 days', 2 = '3 to 4 days', 3 = '5 to 6' days, and 4 = 'every day'). The total score was derived by summing scores of all 7-items. Total score ranges from 0 (absent disease) to 28 (severe disease). Higher score indicates poor QoL. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose (Week 16) visit value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Scores on a Scale
Change From Baseline in PRO Measure of Patient Oriented Eczema Measure (POEM) at Week 16
Scores on a ScalePlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in PRO Measure of Patient Oriented Eczema Measure (POEM) at Week 16-4.36 ± 7.427-4.59 ± 5.917-8.58 ± 7.058-4.63 ± 4.745-7.68 ± 8.759
SecondaryChange From Baseline in PRO Measure of Dermatology Life Quality Index (DLQI) Score at Week 16

The DLQI is a 10-item questionnaire that asks participants to evaluate the degree that their skin disease has affected their QoL. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score. The total DLQI score ranges from 0 (not at all) to 30 (very much). Higher scores indicated more impaired quality of life. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Scores on a Scale
Change From Baseline in PRO Measure of Dermatology Life Quality Index (DLQI) Score at Week 16
Scores on a ScalePlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in PRO Measure of Dermatology Life Quality Index (DLQI) Score at Week 16-5.00 ± 8.477-4.63 ± 8.321-8.48 ± 8.424-3.94 ± 6.458-7.56 ± 7.201
SecondaryChange From Baseline in PRO Measure of Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale Score at Week 16

HADS was a validated 14-item self-reported questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale. HADS-A assessed state of generalized anxiety. It comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 (no, not at all) to 3 (yes, definitely), where higher scores indicated more anxiety/depression symptoms. HADS-A total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicated greater severity of anxiety. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value. Data of HADS-anxiety subscale score has been presented.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Scores on a Scale
Change From Baseline in PRO Measure of Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale Score at Week 16
Scores on a ScalePlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in PRO Measure of Hospital Anxiety and Depression Scale (HADS) - Anxiety Subscale Score at Week 16-0.67 ± 3.585-1.05 ± 2.297-2.21 ± 3.735-0.50 ± 4.356-1.94 ± 4.183
SecondaryChange From Baseline in PRO Measure of HADS-Depression Subscale Score at Week 16

HADS was a validated 14-item self-reported questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale. HADS-D assessed state of depression. It comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 (no, not at all) to 3 (yes, definitely), where higher scores indicated more anxiety/depression symptoms. HADS-D total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicated greater severity of depression. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value. Data of HADS-depression subscale score has been presented.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Scores on a Scale
Change From Baseline in PRO Measure of HADS-Depression Subscale Score at Week 16
Scores on a ScalePlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in PRO Measure of HADS-Depression Subscale Score at Week 16-1.53 ± 3.803-0.84 ± 2.734-1.11 ± 3.6350.50 ± 3.650-1.88 ± 3.982
SecondaryChange From Baseline in PRO Measure of Work Productivity and Activity Impairment Questionnaire-Atopic Dermatitis (WPAI- AD) at Week 16

The WPAI-AD is a concise,6-item questionnaire that evaluates the impact of atopic dermatitis on both work and daily activities, yielding 4 percentage-based impairment scores, each range from 0 to 100%. Higher values=greater impairment. Calculation of these 4 scores are as follows: 1. Work time missed due to health (Absenteeism) (%)=hours missed due to health divided by (hours missed due to health+hours missed for other reasons+hours actually worked) \*100. 2. Impairment while working due to health (Presenteeism) (%)=Question (Q)5 score (from 0 to 10) divided by 10\*100. 3. Overall work impairment due to health (%)=Absenteeism+(1-Absenteeism fraction)\*Presenteeism. 4. Activity impairment due to health (%)=Q6 score (from 0 to 10) divided by 10\*100.Baseline was the last value/assessment before the first dose of study treatment (Day1) based on date and time of the assessment and treatment. CFB was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Scores on a Scale
Change From Baseline in PRO Measure of Work Productivity and Activity Impairment Questionnaire-Atopic Dermatitis (WPAI- AD) at Week 16
Scores on a ScalePlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Work time missed due to health-4.43 ± 9.29415.76 ± 32.405-4.54 ± 28.375-1.31 ± 8.937-0.84 ± 21.263
Impairment while working due to health-20.00 ± 46.726-23.33 ± 34.641-15.45 ± 23.394-14.17 ± 19.752-9.41 ± 32.301
Overall work impairment due to health-21.23 ± 44.566-21.48 ± 36.722-13.59 ± 24.074-13.33 ± 20.117-8.14 ± 35.238
Activity impairment due to health-24.67 ± 38.572-15.56 ± 27.912-26.32 ± 22.903-13.33 ± 27.865-21.21 ± 28.147
SecondaryNumber of Participants With Adverse Events (AEs), Serious AE (SAEs), and AEs of Special Interest (AESI)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with use of a study intervention, whether or not considered related to study intervention. Any untoward medical occurrence that, at any dose, results in death, Is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes, Is a suspected transmission of any infectious agent via an authorized medicinal product and medically important were categorized as SAE. AESIs of the study drug includes serious and opportunistic infections, serious hypersensitivity reactions and injection site reactions.

Time frame:
Up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs), Serious AE (SAEs), and AEs of Special Interest (AESI)
ParticipantsPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
AEs2112151323
SAEs00011
AESIs00011
SecondaryChange From Baseline in Hematology Parameter: Hemoglobin (Hb)

Blood samples were collected to analyze hematology parameter: hemoglobin. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Grams per Liter
Change From Baseline in Hematology Parameter: Hemoglobin (Hb)
Grams per LiterPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in Hematology Parameter: Hemoglobin (Hb)-2.3 ± 7.070.5 ± 15.12-0.3 ± 11.45-3.7 ± 3.95-1.1 ± 8.60
SecondaryChange From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets

Blood samples were collected to analyze Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · 10^9 cells per liter
Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Leukocytes, Lymphocytes, Monocytes, Neutrophils and Platelets
10^9 cells per literPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Basophils-0.008 ± 0.03800.004 ± 0.0299-0.004 ± 0.03720.004 ± 0.0342-0.007 ± 0.0342
Eosinophils0.020 ± 0.5437-0.187 ± 0.36510.053 ± 0.2918-0.139 ± 0.4575-0.044 ± 0.3114
Leukocytes-0.92 ± 4.0500.35 ± 1.512-0.05 ± 1.4520.49 ± 2.388-0.21 ± 1.978
Lymphocytes-0.084 ± 0.52020.066 ± 0.51620.071 ± 0.57370.256 ± 0.49430.123 ± 0.3357
Monocytes-0.062 ± 0.2711-0.012 ± 0.13890.007 ± 0.1614-0.120 ± 0.1966-0.056 ± 0.1478
Neutrophils-0.782 ± 3.80720.481 ± 1.5835-0.183 ± 1.14840.489 ± 2.1748-0.234 ± 1.9582
Platelets3.3 ± 39.86-13.2 ± 32.911.5 ± 29.49-7.3 ± 43.32-3.0 ± 30.33
SecondaryChange From Baseline in Hematology Parameter: Erythrocytes

Blood samples were collected to analyze hematology parameter: erythrocytes. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · 10^12 cells per liter
Change From Baseline in Hematology Parameter: Erythrocytes
10^12 cells per literPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in Hematology Parameter: Erythrocytes-0.04 ± 0.2150.11 ± 0.4820.03 ± 0.330-0.09 ± 0.145-0.04 ± 0.243
SecondaryChange From Baseline in Hematology Parameter: Hematocrit

Blood samples were collected to analyze hematology parameter: hematocrit. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematology Parameter: Hematocrit
Proportion of red blood cells in bloodPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in Hematology Parameter: Hematocrit-0.0031 ± 0.02730.0047 ± 0.04270.0014 ± 0.0301-0.0100 ± 0.01550.0022 ± 0.0230
SecondaryChange From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio

Blood samples were collected to analyze hematology parameter: Prothrombin International Normalized Ratio. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Ratio
Change From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio
RatioPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in Hematology Parameter: Prothrombin International Normalized Ratio-0.021 ± 0.1172-0.042 ± 0.1522-0.036 ± 0.14870.052 ± 0.2580-0.038 ± 0.1525
SecondaryChange From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma-Glutamyl Transferase (GGT)

Blood samples were collected to analyze clinical chemical parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma-Glutamyl Transferase (GGT). Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · International Units per Liter
Change From Baseline in Clinical Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Gamma-Glutamyl Transferase (GGT)
International Units per LiterPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
ALT-2.6 ± 12.94-3.7 ± 16.80-2.2 ± 14.25-2.0 ± 10.65-1.8 ± 7.82
ALP-2.4 ± 19.19-6.4 ± 18.87-1.8 ± 11.51-2.3 ± 11.33-6.1 ± 9.45
AST-2.2 ± 10.47-4.9 ± 10.93-2.5 ± 5.78-3.6 ± 7.51-1.1 ± 5.99
GGT-3.3 ± 19.990.3 ± 16.57-1.1 ± 3.501.6 ± 12.720.5 ± 6.36
SecondaryChange From Baseline in Clinical Chemistry Parameter: Total Bilirubin, Direct Bilirubin, and Creatinine

Blood samples were collected to analyze clinical chemical parameters: Total Bilirubin, Direct Bilirubin, and Creatinine. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Micromoles per (/) Liter
Change From Baseline in Clinical Chemistry Parameter: Total Bilirubin, Direct Bilirubin, and Creatinine
Micromoles per (/) LiterPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Total Bilirubin0.2 ± 4.400.2 ± 4.540.2 ± 5.10-0.5 ± 2.52-1.8 ± 4.29
Direct Bilirubin0.2 ± 0.880.1 ± 1.090.0 ± 1.43-0.2 ± 0.69-0.2 ± 0.76
Creatinine0.2 ± 5.33-0.3 ± 9.221.4 ± 12.480.7 ± 5.89-2.8 ± 8.13
SecondaryChange From Baseline in Chemistry Parameters: Glucose and Urea

Blood samples were collected to analyze chemistry parameters: glucose and urea. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Millimoles per liter
Change From Baseline in Chemistry Parameters: Glucose and Urea
Millimoles per literPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Glucose-0.03 ± 0.6180.01 ± 0.6750.25 ± 0.7140.02 ± 0.9100.04 ± 0.781
Urea-0.31 ± 1.046-0.19 ± 1.3320.14 ± 1.2280.00 ± 0.9600.21 ± 1.267
SecondaryChange From Baseline in Chemistry Parameter: Albumin

Blood samples were collected to analyze chemistry parameter: albumin. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Grams per liter
Change From Baseline in Chemistry Parameter: Albumin
Grams per literPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in Chemistry Parameter: Albumin0.3 ± 2.60-0.2 ± 3.250.0 ± 3.29-1.4 ± 2.19-0.6 ± 2.07
SecondaryChange From Baseline in Chemistry Parameter: Estimated Glomerular Filtration Rate

Blood samples were collected to analyze chemistry parameter: Estimated Glomerular Filtration Rate. Baseline was the last value/assessment before the first dose of study treatment (Day 1) based on date and time of the assessment and treatment. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit (Week 16) value.

Time frame:
Baseline (Day 1) and Week 16
Reported as:
Mean · Milliliter/second/1.73 square meter
Change From Baseline in Chemistry Parameter: Estimated Glomerular Filtration Rate
Milliliter/second/1.73 square meterPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Change From Baseline in Chemistry Parameter: Estimated Glomerular Filtration Rate-0.0085 ± 0.09674-0.0055 ± 0.15910-0.0401 ± 0.22359-0.0131 ± 0.098380.0454 ± 0.17785
SecondaryNumber of Participants With Greater Than or Equal to (>=) Grade 3 Hematological/Clinical Chemistry Abnormalities According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)

The laboratory measurements included hematology and clinical chemistry. The parameters evaluated were albumin, glomerular filtration rate from creatinine adjusted for body surface area, glucose, potassium, sodium, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, creatinine, gamma glutamyl transferase, activated partial thromboplastin time, hemoglobin, leukocytes, lymphocytes, neutrophils, platelets, prothrombin international normalized ratio, eosinophils, and fibrinogen. Worst case grade increase from Baseline grade was evaluated for all the laboratory tests that were gradable by NCI CTCAE. Data is presented for only those parameters for which participants had worst case \>= Grade 3 abnormalities.

Time frame:
Up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Greater Than or Equal to (>=) Grade 3 Hematological/Clinical Chemistry Abnormalities According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
ParticipantsPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Number of Participants With Greater Than or Equal to (>=) Grade 3 Hematological/Clinical Chemistry Abnormalities According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)11012

Adverse events

Collected over Up to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/46 (0%)0/46 (0%)10/46 (21.7%)
GSK1070806 Dose Level 10/21 (0%)0/21 (0%)5/21 (23.8%)
GSK1070806 Dose Level 20/25 (0%)0/25 (0%)9/25 (36%)
GSK1070806 Dose Level 30/21 (0%)1/21 (4.8%)9/21 (42.9%)
GSK1070806 Dose Level 40/46 (0%)1/46 (2.2%)12/46 (26.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
Hodgkin's disease nodular sclerosisNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/460/210/251/210/46
Generalised tonic-clonic seizureNervous system disorders0/460/210/250/211/46
Most frequent other events
Showing 10 of 11
Most frequent other events
EventPlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4
NasopharyngitisInfections and infestations1/461/212/255/217/46
HeadacheNervous system disorders3/460/210/254/211/46
Dermatitis atopicSkin and subcutaneous tissue disorders2/464/211/251/211/46
FolliculitisInfections and infestations1/460/210/253/212/46
EosinophiliaBlood and lymphatic system disorders0/460/210/252/211/46
HordeolumInfections and infestations0/460/210/252/210/46
PruritusSkin and subcutaneous tissue disorders1/461/211/252/212/46
SinusitisInfections and infestations0/461/212/251/210/46
Back painMusculoskeletal and connective tissue disorders0/460/212/250/211/46
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/460/212/250/210/46

Baseline characteristics

Baseline characteristics were reported for Full Analysis Set (FAS) which included all randomized participants who received at least 1 dose of study treatment. This population was based on the treatment the participant was randomized to.

Age, Continuous
Age, Continuous(YEARS)PlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4Total
Mean37.7 ± 14.4234.1 ± 12.7239.2 ± 14.9435.3 ± 8.9640.1 ± 13.6037.8 ± 13.45
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4Total
Female2378101967
Male231417112792
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboGSK1070806 Dose Level 1GSK1070806 Dose Level 2GSK1070806 Dose Level 3GSK1070806 Dose Level 4Total
AMERICAN INDIAN OR ALASKA NATIVE211116
ASIAN158961654
BLACK OR AFRICAN AMERICAN4002612
WHITE201011102071
MIXED RACE310105
NOT REPORTED212128
UNKNOWN002013
08

Study locations

89 sites
  • GSK Investigational Site
    Phoenix, Arizona 85006, United States
  • GSK Investigational Site
    North Little Rock, Arkansas 72117, United States
  • GSK Investigational Site
    Canoga Park, California 91303, United States
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Northridge, California 91325, United States
  • GSK Investigational Site
    Oceanside, California 92056, United States
  • GSK Investigational Site
    Santa Monica, California 90404, United States
  • GSK Investigational Site
    Homestead, Florida 33033, United States
  • GSK Investigational Site
    Oakland Park, Florida 33334, United States
  • GSK Investigational Site
    Fayetteville, Georgia 30214, United States
  • GSK Investigational Site
    Thomasville, Georgia 31792, United States
  • GSK Investigational Site
    Chicago, Illinois 60614, United States
  • GSK Investigational Site
    Troy, Michigan 48084, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    New York, New York 10075, United States
  • GSK Investigational Site
    Dublin, Ohio 43016, United States
  • GSK Investigational Site
    West Lake Hills, Texas 78746, United States
  • GSK Investigational Site
    Buenos Aires, C1055AAO, Argentina
  • GSK Investigational Site
    Capital Federal, C1181ACH, Argentina
  • GSK Investigational Site
    Ciudad Autonoma de Bueno, C1056ABI, Argentina
  • GSK Investigational Site
    Córdoba, X5000AAW, Argentina
  • GSK Investigational Site
    Mendoza, 5500, Argentina
  • GSK Investigational Site
    Rosario, S2002, Argentina
  • GSK Investigational Site
    Pleven, 5800, Bulgaria
  • GSK Investigational Site
    Sofia, 1510, Bulgaria
  • GSK Investigational Site
    Sofia, Bulgaria
  • GSK Investigational Site
    Kelowna, British Columbia V1Y 4N7, Canada
  • GSK Investigational Site
    Barrie, Ontario L4M 7G1, Canada
  • GSK Investigational Site
    London, Ontario N6H 5L5, Canada
  • GSK Investigational Site
    Markham, Ontario L3P1X2, Canada
  • GSK Investigational Site
    Québec, Quebec G1W 4R4, Canada
  • GSK Investigational Site
    Beijing, 100044, China
  • GSK Investigational Site
    Chongqing, 400016, China
  • GSK Investigational Site
    Fuzhou, 350014, China
  • GSK Investigational Site
    Guangzhou, China
  • GSK Investigational Site
    Hangzhou, 310006, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Shanghai, China
  • GSK Investigational Site
    Yinchuan, China
  • GSK Investigational Site
    Yiwu, 322000, China
  • GSK Investigational Site
    Prague, 10034, Czechia
  • GSK Investigational Site
    Prague, 128 08, Czechia
  • GSK Investigational Site
    Prague, Czechia
  • GSK Investigational Site
    La Rochelle, 17019, France
  • GSK Investigational Site
    Paris, 75475, France
  • GSK Investigational Site
    Berlin, 10789, Germany
  • GSK Investigational Site
    Hamburg, 22391, Germany
  • GSK Investigational Site
    Münster, 48149, Germany
  • GSK Investigational Site
    Athens, Greece
  • GSK Investigational Site
    Bari, 70124, Italy
  • GSK Investigational Site
    Bologna, 40138, Italy
  • GSK Investigational Site
    Florence, Italy
  • GSK Investigational Site
    Modena, 41124, Italy
  • GSK Investigational Site
    Roma, 00128, Italy
  • GSK Investigational Site
    Roma, 00168, Italy
  • GSK Investigational Site
    Chiba, 272-0033, Japan
  • GSK Investigational Site
    Fukuoka, 807-8556, Japan
  • GSK Investigational Site
    Fukuoka, 812-8582, Japan
  • GSK Investigational Site
    Gunma, 370-0829, Japan
  • GSK Investigational Site
    Hokkaido, 060-0033, Japan
  • GSK Investigational Site
    Hokkaido, 080-0013, Japan
  • GSK Investigational Site
    Kanagawa, 211-0063, Japan
  • GSK Investigational Site
    Osaka, 583-8588, Japan
  • GSK Investigational Site
    Osaka, 593-8324, Japan
  • GSK Investigational Site
    Saitama, 343-8555, Japan
  • GSK Investigational Site
    Chihuahua City, 31000, Mexico
  • GSK Investigational Site
    Durango, 34000, Mexico
  • GSK Investigational Site
    Guadalajara, 44628, Mexico
  • GSK Investigational Site
    Monterrey, 64718, Mexico
  • GSK Investigational Site
    Panama City, 7099, Panama
  • GSK Investigational Site
    Chojnice, 89-600, Poland
  • GSK Investigational Site
    Elblag, 82-300, Poland
  • GSK Investigational Site
    Katowice, 40-600, Poland
  • GSK Investigational Site
    Poznan, 60-569, Poland
  • GSK Investigational Site
    Szczecin, 70-332, Poland
  • GSK Investigational Site
    Warsaw, 03-291, Poland
  • GSK Investigational Site
    Ansan, 15355, South Korea
  • GSK Investigational Site
    Seoul, 03722, South Korea
  • GSK Investigational Site
    Seoul, 04564, South Korea
  • GSK Investigational Site
    Seoul, 04763, South Korea
  • GSK Investigational Site
    Seoul, 150-950, South Korea
  • GSK Investigational Site
    Alicante, 03010, Spain
  • GSK Investigational Site
    Córdoba, 14004, Spain
  • GSK Investigational Site
    Granada, 18016, Spain
  • GSK Investigational Site
    Madrid, 28222, Spain
  • GSK Investigational Site
    Vigo, 36206, Spain
  • GSK Investigational Site
    Zaragoza, 50009, Spain
  • GSK Investigational Site
    Bangkok, 10330, Thailand
  • GSK Investigational Site
    Pathum Thani, 12120, Thailand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Jul 2025, 20 months.

Results were first posted in Jun 2026, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2023
First posted
Aug 21, 2023
StartActual
Nov 16, 2023
Primary completionActual
Jul 23, 2025
CompletionActual
Jul 23, 2025
Results first posted
Jun 3, 2026
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05999799
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Nov 16, 2023
Primary completion
Jul 23, 2025
Completion
Jul 23, 2025
Results posted
Jun 3, 2026
Last update
Jun 3, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1070806

Start the discussion